mangalore today
name
name
name
Thursday, May 26
Genesis Engineersnamename

 

Covishield, Covaxin likely to be capped at Rs 275 per dose post regular market approval


Mangalore Today News Network

New Delhi, Jan 26, 2022: The price of Covishield and Covaxin, the COVID-19 vaccines which are expected to soon get regular market approval from India’s drug regulator, is likely to be capped at Rs 275 per dose plus an additional service charge of Rs 150, official sources said.

 

covaxin-covishield


According to them, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines affordable.

As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the country.

A Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organisation on January 19 recommended granting regular market approval to Covid vaccines Covishield and Covaxin for use in the adult population subject to certain conditions.

"The NPPA has been asked to work towards capping the price of the vaccines. The price is likely to be capped at Rs 275 per dose along with an additional service charge of Rs 150," an official source said.

Prakash Kumar Singh, the director (government and regulatory affairs) at Serum Institue of India, had submitted an application to the Drugs Controller General of India on October 25 seeking regular market approval for its Covishield vaccine.

A couple of weeks ago, V Krishna Mohan, the whole-time director at Bharat Biotech, submitted complete information on the chemistry, manufacturing and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.

Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.


Courtesy:The News Minute


Write Comment | E-Mail To a Friend | Facebook | Twitter | Print
Write your Comments on this Article
Your Name
Native Place / Place of Residence
Your E-mail
Your Comment
You have characters left.
Security Validation
Enter the characters in the image above